Safety and Genetic Stability of Cultured Perinatal Mesenchymal Stem Cells

  • Youwei Wang


Perinatal mesenchymal stem cells are considered as a promising tool to treat many diseases in clinical studies. Being different with chemical or protein drugs, perinatal stem cells were used as living cells. No method is well established to evaluate the safety issues of perinatal mesenchymal stem cells. This is a challenge not only for patients and physicians but also for manufacturers and administrators. Safety issues of perinatal stem cells could come from perinatal stem cells themselves, which include, but not limited to, cytokine storm, unwanted differentiation, and tumorigenesis. Other safety concerns of perinatal stem cells are related to processing and quality control when processing or manufacturing mesenchymal stem cells. After in vitro expansion, which is inevitable for clinical application, perinatal mesenchymal stem cells may change their biological characteristics. So it is critical to answer whether in vitro culture decreases the clinical value of perinatal mesenchymal stem cells or increases any risk for the clinical application. Preclinical studies and clinical data, quality control, and potential risk factors for manufacturing and clinical application will be discussed in this chapter.


  1. 1.
    Lu LL, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006;91(8):1017–26.PubMedGoogle Scholar
  2. 2.
    Ra JC, et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011;20(8):1297–308.PubMedGoogle Scholar
  3. 3.
    Jiang R, et al. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med. 2011;5(1):94–100.PubMedGoogle Scholar
  4. 4.
    Wu Y, et al. Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD. Stem Cell Res. 2014;12(1):132–8.PubMedGoogle Scholar
  5. 5.
    Liang L, et al. Transplantation of human placenta derived mesenchymal stem cell alleviates critical limb ischemia in diabetic nude rat. Cell Transplant. 2017;26(1):45–61.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Leow SN, et al. Safety and efficacy of human Wharton’s jelly-derived mesenchymal stem cells therapy for retinal degeneration. PLoS One. 2015;10(6):e0128973.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Parys M, et al. Safety of intraperitoneal injection of adipose tissue-derived autologous mesenchymal stem cells in cats. J Vet Intern Med. 2016;30(1):157–63.PubMedGoogle Scholar
  8. 8.
    Van Loon VJ, et al. Clinical follow-up of horses treated with allogeneic equine mesenchymal stem cells derived from umbilical cord blood for different tendon and ligament disorders. Vet Q. 2014;34(2):92–7.PubMedGoogle Scholar
  9. 9.
    Park YB, et al. Effect of transplanting various concentrations of a composite of human umbilical cord blood-derived mesenchymal stem cells and hyaluronic acid hydrogel on articular cartilage repair in a rabbit model. PLoS One. 2016;11(11):e0165446.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Jang KM, et al. Efficacy and safety of human umbilical cord blood-derived mesenchymal stem cells in anterior cruciate ligament reconstruction of a rabbit model: new strategy to enhance tendon graft healing. Arthroscopy. 2015;31(8):1530–9.PubMedGoogle Scholar
  11. 11.
    Park YB, et al. Cartilage regeneration in osteoarthritic patients by a composite of allogeneic umbilical cord blood-derived Mesenchymal stem cells and hyaluronate hydrogel: results from a clinical trial for safety and proof-of-concept with 7 years of extended follow-up. Stem Cells Transl Med. 2017;6(2):613–21.PubMedGoogle Scholar
  12. 12.
    De Kok IJ, et al. Evaluation of mesenchymal stem cells following implantation in alveolar sockets: a canine safety study. Int J Oral Maxillofac Implants. 2005;20(4):511–8.PubMedGoogle Scholar
  13. 13.
    Wang Y, et al. A toxicity study of multiple-administration human umbilical cord mesenchymal stem cells in cynomolgus monkeys. Stem Cells Dev. 2012;21(9):1401–8.PubMedGoogle Scholar
  14. 14.
    Hu J, et al. Long term effect and safety of Wharton’s jelly-derived mesenchymal stem cells on type 2 diabetes. Exp Ther Med. 2016;12(3):1857–66.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Tisato V, et al. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia. 2007;21(9):1992–9.PubMedGoogle Scholar
  16. 16.
    Li XH, et al. Reduced intensity conditioning, combined transplantation of haploidentical hematopoietic stem cells and mesenchymal stem cells in patients with severe aplastic anemia. PLoS One. 2014;9(3):e89666.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Wang D, et al. Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. Clin Exp Med. 2017;17(3):333–40.PubMedGoogle Scholar
  18. 18.
    Wang D, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014;16(2):R79.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Liang J, et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. Gut. 2012;61(3):468–9.PubMedGoogle Scholar
  20. 20.
    Zhang Z, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol. 2012;27(Suppl 2):112–20.PubMedGoogle Scholar
  21. 21.
    Li YH, et al. Umbilical cord-derived mesenchymal stem cell transplantation in hepatitis B virus related acute-on-chronic liver failure treated with plasma exchange and Entecavir: a 24-month prospective study. Stem Cell Rev. 2016;12(6):645–53.PubMedGoogle Scholar
  22. 22.
    Shi M, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med. 2012;1(10):725–31.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Chen G, et al. Monitoring the biology stability of human umbilical cord-derived mesenchymal stem cells during long-term culture in serum-free medium. Cell Tissue Bank. 2014;15(4):513–21.PubMedGoogle Scholar
  24. 24.
    Mark P, et al. Human mesenchymal stem cells display reduced expression of CD105 after culture in serum-free medium. Stem Cells Int. 2013;2013:698076.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Wang Y, et al. Human mesenchymal stem cells possess different biological characteristics but do not change their therapeutic potential when cultured in serum free medium. Stem Cell Res Ther. 2014;5(6):132.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Zhu Y, et al. Alteration of histone acetylation pattern during long-term serum-free culture conditions of human fetal placental mesenchymal stem cells. PLoS One. 2015;10(2):e0117068.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Clark KC, et al. Canine and equine mesenchymal stem cells grown in serum free media have altered immunophenotype. Stem Cell Rev. 2016;12(2):245–56.PubMedGoogle Scholar
  28. 28.
    Buzzard JJ, et al. Karyotype of human ES cells during extended culture. Nat Biotechnol. 2004;22(4):381–2. author reply 382.PubMedGoogle Scholar
  29. 29.
    Draper JS, et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol. 2004;22(1):53–4.PubMedGoogle Scholar
  30. 30.
    Lefort N, et al. Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. Nat Biotechnol. 2008;26(12):1364–6.PubMedGoogle Scholar
  31. 31.
    Spits C, et al. Recurrent chromosomal abnormalities in human embryonic stem cells. Nat Biotechnol. 2008;26(12):1361–3.PubMedGoogle Scholar
  32. 32.
    Ronen D, Benvenisty N. Genomic stability in reprogramming. Curr Opin Genet Dev. 2012;22(5):444–9.PubMedGoogle Scholar
  33. 33.
    von Joest M, Bua Aguin S, Li H. Genomic stability during cellular reprogramming: mission impossible? Mutat Res. 2016;788:12–6.Google Scholar
  34. 34.
    Wang Y, et al. Long-term cultured mesenchymal stem cells frequently develop genomic mutations but do not undergo malignant transformation. Cell Death Dis. 2013;4:e950.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Cai J, et al. Whole-genome sequencing identifies genetic variances in culture-expanded human mesenchymal stem cells. Stem Cell Rep. 2014;3(2):227–33.Google Scholar
  36. 36.
    Miura M, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells. 2006;24(4):1095–103.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Ren Z, et al. Spontaneous transformation of adult mesenchymal stem cells from cynomolgus macaques in vitro. Exp Cell Res. 2011;317(20):2950–7.PubMedGoogle Scholar
  38. 38.
    Ren Z, Zhang YA, Chen Z. Spontaneous transformation of cynomolgus mesenchymal stem cells in vitro: further confirmation by short tandem repeat analysis. Exp Cell Res. 2012;318(5):435–40.PubMedGoogle Scholar
  39. 39.
    Pan Q, et al. Detection of spontaneous tumorigenic transformation during culture expansion of human mesenchymal stromal cells. Exp Biol Med (Maywood). 2014;239(1):105–15.Google Scholar
  40. 40.
    Bernardo ME, et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007;67(19):9142–9.PubMedPubMedCentralGoogle Scholar
  41. 41.
    de la Fuente R, et al. Retraction: spontaneous human adult stem cell transformation. Cancer Res. 2010;70(16):6682.PubMedGoogle Scholar
  42. 42.
    Rubio D, et al. Spontaneous human adult stem cell transformation. Cancer Res. 2005;65(8):3035–9.PubMedGoogle Scholar
  43. 43.
    Garcia S, et al. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res. 2010;316(9):1648–50.PubMedGoogle Scholar
  44. 44.
    Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820–3.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Tu B, et al. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3. Oncotarget. 2016;7(30):48296–308.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Karnoub AE, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–63.PubMedGoogle Scholar
  47. 47.
    Xu WT, et al. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett. 2009;281(1):32–41.PubMedGoogle Scholar
  48. 48.
    De Boeck A, et al. Resident and bone marrow-derived mesenchymal stem cells in head and neck squamous cell carcinoma. Oral Oncol. 2010;46(5):336–42.PubMedGoogle Scholar
  49. 49.
    Li MH, et al. Study of bone mesenchymal stem cells tropism for hepatic tumors and effect on the form of tumor stromal. Zhonghua Yi Xue Za Zhi. 2010;90(5):349–54.PubMedGoogle Scholar
  50. 50.
    Mathew E, et al. Mesenchymal stem cells promote pancreatic tumor growth by inducing alternative polarization of macrophages. Neoplasia. 2016;18(3):142–51.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Coffman LG, et al. Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. Oncotarget. 2016;7(6):6916–32.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Peppicelli S, et al. Extracellular acidity strengthens mesenchymal stem cells to promote melanoma progression. Cell Cycle. 2015;14(19):3088–100.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Shinagawa K, et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer. 2010;127(10):2323–33.PubMedGoogle Scholar
  54. 54.
    Yang X, et al. Human umbilical cord mesenchymal stem cells promote carcinoma growth and lymph node metastasis when co-injected with esophageal carcinoma cells in nude mice. Cancer Cell Int. 2014;14(1):93.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Barcellos-de-Souza P, et al. Mesenchymal stem cells are recruited and activated into carcinoma-associated fibroblasts by prostate cancer microenvironment-derived TGF-beta1. Stem Cells. 2016;34(10):2536–47.PubMedGoogle Scholar
  56. 56.
    Mishra PJ, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 2008;68(11):4331–9.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Zhang K, et al. Bone marrow mesenchymal stem cells induce angiogenesis and promote bladder cancer growth in a rabbit model. Urol Int. 2010;84(1):94–9.PubMedGoogle Scholar
  58. 58.
    Roorda BD, et al. Mesenchymal stem cells contribute to tumor cell proliferation by direct cell-cell contact interactions. Cancer Investig. 2010;28(5):526–34.Google Scholar
  59. 59.
    Martin FT, et al. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat. 2010;124(2):317–26.PubMedGoogle Scholar
  60. 60.
    Zhu W, et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett. 2012;315(1):28–37.PubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Youwei Wang
    • 1
  1. 1.Cell Therapy Lab, James Cancer Hospital, Ohio State UniversityColumbusUSA

Personalised recommendations